VivoSeq
Infectious Disease

Swine Influenza

5

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Swine Influenza is an early-stage landscape with 5 programs across 4 companies. The most active players are Novartis, Sanofi, Glaxo Dba Glaxosmithkline. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

75/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 1Sanofi logo

Sanofi

1 program

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSVaccine125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Terminated1 · 25%

Clinical Trials

Trial Activity

A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection
Terminated·—·Phase 3·NCT00979667·4 enrolled
Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
Completed·Novartis logoNovartis·Phase 1·NCT01855945·627 enrolled
Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects
Completed·Novartis logoNovartis·Phase 2/3·NCT01000207·123 enrolled
Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects
Completed·Novartis logoNovartis·Phase 2/3·NCT00996138·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)